European Leukemia Trial Registry
Trial: RATIFY

More Details
Title Midostaurin in FLT3 + AML
Scientific Title A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) or Placebo in newly diagnosed Patients < 60 years of age with FLT3 Mutated Acute Myeloid Leukemia (AML)
Short Title RATIFY
Trialgroup SAL
Type of Trial multicentric, randomized
Disease Acute myeloid leukemia(AML) AML all subtypes without FAB M3
Age <= 60 years
Status No longer recruiting
Start of Recruitment 01.08.2008
Leader Ehninger, Prof. Dr. med., Gerhard
Contactperson

General Contact Person
Illmer, Dr.med.habil., Th.
Tel: +49 (0)351 4584251
Fax: +49 (0)351 4584251
Email: ratify@uniklinikum-dresden.de

General Contact Person
Schaich, Prof. Dr. med., Markus
Tel: +49 (0)7195 591-39240
Fax: +49 (0)7195 591-939240
Email: markus.schaich@rems-murr-kliniken.de

Study Centre
Lehmann, Gina
Tel: +49 (0)351 458 7172
Fax: +49 (0)351 458 4367
Email: gina.lehmann@uniklinikum-dresden.de

Shortprotocol Shortprotocol
Diagnostics

Molecular Genetics
Hämatologisches Labor, Universitätsklinikum Dresden

Remark www.sal-aml.org
created 14.11.2008 5 Roswitha Kotthoff
changed 06.11.2014 Alexandra Lucaciu
© ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org